The novel coronavirus SARS-CoV-2 continues to cause death and disease throughout the world, underscoring the necessity of understanding the virus and host immune response. From the start of the pandemic, a prominent pattern of central nervous system (CNS) pathologies, including demyelination, has emerged, suggesting an underlying mechanism of viral mimicry to CNS proteins. We hypothesized that immunodominant epitopes of SARS-CoV-2 share homology with proteins associated with multiple sclerosis (MS). Using PEPMatch, a newly developed bioinformatics package which predicts peptide similarity within specific amino acid mismatching parameters consistent with published MHC binding capacity, we discovered that nucleocapsid protein shares significant overlap with 22 MS-associated proteins, including myelin proteolipid protein (PLP). Further computational evaluation demonstrated that this overlap may have critical implications for T cell responses in MS patients and is likely unique to SARS-CoV-2 among the major human coronaviruses. Our findings substantiate the hypothesis of viral molecular mimicry in the pathogenesis of MS and warrant further experimental exploration.
Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) is a novel pathogen that emerged in late 2019 as the causative agent of COVID-19. Due to the resulting global pandemic—there have been approximately 635 million documented cases worldwide1—as well as the novelty of the virus itself, much attention has been focused on post-viral sequalae reported in recovered patients. A significant proportion of these sequelae are related to aberrations in the central nervous system (CNS)2. In fact, 1 in 4 individuals with long-COVID recently reported persistent cognitive deficits and there is an emerging consensus on the significance of long-COVID as a public health burden3. Neurological manifestations have also been reported during acute SARS-CoV-2 infection, including encephalitis, encephalomyelitis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis4. Taken together, these manifestations suggest a pathogenesis potentially involving demyelination, which may further suggest the centrality of an autoimmune process in both acute and post-infectious clinical presentations in some COVID-19 patients.
Multiple sclerosis (MS) is the most common autoimmune demyelinating disease in the United States and affects approximately 3 million people worldwide5. It has been widely suggested that the etiology of MS involves an initial infectious insult. For decades, it has been noted that the onset of first and recurring episodes of MS are often preceded by acute infections6,7,8. Importantly, studies investigating seasonal coronaviruses and SARS-CoV-2 have suggested the ability of these viruses to elicit cross-reactivity with viruses thought to play a role in the initial pathogenesis of MS9. In addition, other notable autoimmune diseases such as Guillain–Barre Syndrome, hypothesized to be driven in part by molecular mimicry, have been reported following SARS-CoV-2 infection10. We hypothesized that SARS-CoV-2 proteins share homology with CNS proteins, which could play a role in the physical manifestations of MS following acute SARS-CoV-2 infection.
Although the development of MS is likely a coalescence of the cellular and humoral adaptive immune arms, T cells have been implicated as being central drivers of disease manifestation in both the mouse model of MS (experimental autoimmune encephalitis, EAE) and humans11,12. Central to the theory of molecular mimicry is the degenerative nature of both T cells and MHC binding, in which multiple peptides can bind to the same MHC, and in turn multiple peptide:MHC combinations can be recognized by the same T cell Receptor (TCR)13,14. Several pathogenic proteins have been assessed for their homology to MS-associated antigens15,16, but no analyses to date have fully captured physiological parameters like MHC degeneracy and peptide length restrictions to provide a comprehensive picture of homology in the context of MHC presentation.
Here, we use PEPMatch17, a newly developed, bioinformatic homology-based package, to assess the potential for molecular mimicry between known immunodominant proteins from SARS-CoV-2 and MS-associated proteins in the context of a T-cell mediated response. Critically, PEPMatch has built-in parameters for both peptide length and mismatching rate, which more closely mimics the constraints imposed by MHC presentation of peptides to TCRs and thus the potential for molecular mimicry. We report that nucleocapsid protein from SARS-CoV-2 shares significant overlap with MS-associated proteins, including the canonical MS protein, myelin proteolipid protein (PLP). Our computational study substantiates the molecular mimicry hypothesis in the neurological sequelae of SARS-CoV-2 infection and lays the groundwork for future experimental and epidemiological studies investigating MS pathogenic etiologies.
SARS-CoV-2 nucleocapsid exhibits significant homology with MS-associated proteins across both 9mer and 15mer peptide groups
We used PEPMatch17 to determine the sequence homology between immunodominant proteins from SARS-CoV-2 and MS-associated proteins, which were compiled using the Immune Epitope Database and Analysis Resource (IEDB) (http://www.iedb.org/) (Table 1). We tested both 9mer and 15mer segments to contextualize MHC I and MHC II presentation, respectively. These peptide lengths correspond to experimentally validated epitope lengths associated with CD8+ and CD4+ T cell recognition, respectively17. Intriguingly, nucleocapsid protein shared significant overlap with MS-associated proteins in both 9mer and 15mer groups (Fig. 1A) (see Methods for full details on background controls and statistical comparisons). Spike, membrane, NS7a, and envelope proteins from SARS-CoV-2 did not share significant overlap with the list of MS proteins above their sequence-shuffled controls, and replicase polyprotein 1ab had significantly elevated peptide matches above its sequence-shuffled control only in the 15mer group (Fig. 1B–F). Out of the 108 antigens on the list of MS-associated proteins used in this analysis, 22 proteins had sequences matching nucleocapsid across both 9mer and 15mer groups. Of note, the canonical MS-associated protein PLP shared homology with nucleocapsid from SARS-CoV-2 (Fig. 1G).
PEPMatch-predicted PLP epitope shares homology with experimentally validated MS-associated peptides and is in a region known to elicit T-cell responses in MS patients
To contextualize the above findings, we investigated whether epitopes returned from PEPMatch had been documented in the literature. We found that of all the proteins returned from the PEPMatch analysis, PLP had the highest number of BLASTp-verified homologous sequences that have been experimentally validated and curated on the IEDB (Fig. 2A,B). PLP has been documented to contain epitopes recognized by T cells from MS patients across numerous studies18,19. In one study, T cell lines derived from MS patients and activated with PLP showed the strongest reactivity against regions 40–60, 95–117, 117–150, and 185–206 out of all 9 regions of PLP tested20. The authors concluded from this study that these regions were largely responsible for eliciting strong T cell responses in MS patients. We found that the PLP peptides returned from PEPMatch fell within one of these immunodominant regions (Fig. 2C). Overall, these results provide a computational basis for the potential of SARS-CoV-2 to initiate T-cell-driven molecular mimicry through specific MS-associated proteins, including PLP.
MHC-binding prediction reveals other proteins of interest which may facilitate molecular mimicry beyond PLP
Given that molecular mimicry is likely facilitated not only by sequence similarity but also by HLA haplotype6,21, we next investigated whether MS-associated alleles22,23,24 would be predicted to bind to the nucleocapsid peptides returned from the PEPMatch analysis. We compared the binding propensity of MS-associated alleles to a set of alleles which represent approximately 99% of the population worldwide to contextualize the analysis25. We analyzed the top 50th percentile of binding predictions returned from the algorithm in order to focus on physiologically relevant binding predictions while retaining maximum information on the alleles26. We found that while some MS-associated alleles demonstrated high average binding capacities (represented by low average percentile rank, Fig. 3A), including HLA-DRB1*03:01, HLA-DRB1*04:04, and HLA-DRB1*08:01, there was no significant difference in average binding predictions from MS-associated alleles in comparison to the reference set of alleles (Fig. 3B). We next asked whether certain proteins matching the nucleocapsid peptides from the original PEPMatch analysis were enriched amongst the top peptide:allele binding predictions. Inspection of these peptide:allele combinations that scored a 10th percentile rank or less across all alleles revealed unique proteins enriched for predicted MHC binding (Fig. 3C). Although our focus has largely centered on the canonical MS protein PLP, this analysis highlights other potential proteins returned from the PEPMatch analysis that may trigger autoimmunity across a wide variety of HLA-haplotyped individuals, including CD99 (Fig. 3C).
Seasonal coronaviruses share significant homology with MS-associated proteins but do not overlap with PLP
Seasonal coronaviruses have been implicated in the development of MS27,28,29. To determine whether the above findings were unique to SARS-CoV-2, we tested whether nucleocapsid, spike, or membrane proteins from seasonal coronaviruses 229E, NL63, OC43, and HKU1 shared significant homology with MS-associated proteins. We found that the nucleocapsid protein from 3 out of the 4 seasonal coronaviruses tested shared significant homology with MS-associated proteins, but only in the 15mer groups (Fig. 4A); due to the stricter matching parameters of the 9mer group, this suggests a higher degree of peptide similarity between SARS-CoV-2 nucleocapsid and MS-associated proteins (Fig. 1A). Nucleocapsid proteins of these 3 seasonal coronaviruses also share the highest percent identity to SARS-CoV-2 nucleocapsid as determined by BLASTp (Fig. 4B). Of note, while the coronaviruses all had some shared PEPMatch protein “hits”, only PLP significantly overlapped with the nucleocapsid of SARS-CoV-2 (Fig. 4C).
Since the beginning of the pandemic, SARS-CoV-2 has been associated with CNS sequelae with manifestations ranging from memory loss and attention deficits to demyelination3,4,30,31. Although viral molecular mimicry has been a long-standing hypothesis regarding the triggering of initial and recurrent episodes of MS demyelination7, no bioinformatic approaches had been created which consider physiological parameters necessary for fully understanding MHC presentation capacity. In this analysis, we demonstrated that SARS-CoV-2 may be associated with the development of MS using a new computational tool developed by the IEDB team that includes more robust physiological parameters in its assessment for homology.
SARS-CoV-2 nucleocapsid, spike, and membrane proteins have been widely demonstrated to elicit strong immune responses32. Indeed, it was recently found that these 3 proteins were among the 9 viral proteins making up 83% of CD4+ T cell responses, and among the 8 accounting for 81% of CD8+ T cell responses in COVID-convalescent patients33,34. In addition, NS7a35, replicase polyprotein1ab36, and envelope37 proteins have all been implicated in driving immune responses in individuals recovering from SARS-CoV-2. We asked whether any of these proteins shared significant homology with MS-associated neuro-antigens—an observation which would fortify the proposed case for molecular mimicry in the development of MS following SARS-CoV-2 infection. Interestingly, both the 9mer and 15mer groups (representing MHC I and II, respectively) from nucleocapsid showed significant sequence overlap with MS-associated proteins (Fig. 1A), in contrast to most of the other proteins tested in our analysis with the exception of replicase polyprotein 1ab, which showed significance only in the 15mer group (Fig. 1E). Given the strict parameters for amino acid homology for the 9mer group—protein sequences had to exactly match a minimum of 78% of the time—a strong overlap of nucleocapsid and MS-associated proteins highlights the potential for SARS-CoV-2-mediated molecular mimicry across both classes of MHC.
Myelin proteolipid protein (PLP) has been implicated in the development of MS across a multitude of studies20,38,39,40. In humans, the development of MS following Rubella virus infection was demonstrated to be linked to the high relative similarity score of E2 protein to PLP16,41, demonstrating the potential for sequence overlap leading to the induction of demyelinating disease. More recently, França et al. discovered that the NS5 epitope of Zika virus shared 83% sequence homology with PLP, implicating NS5 as a likely candidate for driving the development of MS and possibly other CNS inflammatory demyelinating disorders42. In our own study using PEPMatch, we found that an epitope from PLP shared significant homology with a nucleocapsid peptide from SARS-CoV-2 (Fig. 1G). Importantly, the PLP epitope that overlaps with nucleocapsid is associated with a high number of experimentally validated epitopes curated from the literature (Fig. 2A,B), providing evidence for the potential for SARS-CoV-2-driven molecular mimicry. Among the numerous studies that have investigated the autoantigenicity of specific epitopes of PLP in the context of MS-development18,19, certain epitopes have been specifically associated with eliciting strong T cell responses in MS patients20. The epitope returned from PEPMatch in our study, 120–134, is encompassed within an epitope associated with strong T cell responses in DR15*01-positive MS subjects20 (Fig. 2C). Collectively, this data substantiates the hypothesis that SARS-CoV-2 nucleocapsid may be providing the basis for molecular mimicry preceding the development of MS in susceptible individuals.
In the words of Wekerle, “Molecular mimicry thus goes well beyond the simple structural resemblance of two individual peptides. It also embraces the peptide-presenting MHC…”7. We investigated whether nucleocapsid peptides returned from PEPMatch would be predicted to bind preferentially to MS-associated class II HLA alleles, of which more has been published in relation to MS susceptibility than for class I HLA. Using the top 50th percentile of binding predictions, the average percentile rank of all peptide:allele combinations grouped by allele demonstrated no significant pattern of binding enrichment among the MS-associated alleles (Fig. 3B). Several salient considerations must be acknowledged when interpretating these data, however. Importantly, weakly binding peptide epitopes from myelin basic protein (MBP) have been associated with eliciting strong autoimmune responses in EAE mouse models43, suggesting that predicting the binding propensity of peptide:allele combinations may be more complex than fully accounted for by this machine learning algorithm. This analysis also is limited in scope by the total number of HLA alleles assessed. We analyzed 31 alleles; there are over 33,000 allele and haplotype entries on the IPD/IMGT-HLA database44. However, our results suggest that certain HLA alleles not previously associated with MS development may increase susceptibility to CNS-related sequelae, including HLA-DRB4*01:01, though this speculation warrants further investigation.
Top ranking MS-associated alleles from our analysis, including HLA-DRB1*03:01, have not only been associated with the development of MS, but also the development of other autoimmune disorders. HLA-DRB1*03:01 has been associated with autoimmune hepatitis45, autoimmune encephalitis46, neuromyelitis optica47, and autoimmune Addison’s disease (AAD)48. AAD has been reported in the literature following acute COVID-19 infection49,50,51, suggesting that this allele may predispose individuals of this haplotype to other acute autoimmune-related manifestations of SARS-CoV-2 beyond CNS pathologies. In conclusion, numerous studies have been published which link specific HLA haplotypes with susceptibility of severe COVID outcomes52,53,54; however, no studies exist to date which explore the haplotypes of individuals with rare CNS sequelae following SARS-CoV-2 infection. Future experimental investigation should broaden the scope of disease manifestations to better understand the potential link between HLA haplotype and SARS-CoV-2 neuropathogenesis.
To further explore the relationship between allele binding predictions and CNS manifestations, we gathered the peptides of percentile rank 10 or lower26 and tallied the original proteins from which the peptides originated. We found a considerable enrichment of CD99 peptides among the top allele binding predictions (Fig. 3C). CD99 is a cell surface protein expressed by a wide number of tissues and organ systems, including lymphocytes, and is critical for cellular adhesion, migration, and diapedesis55. Recently, CD99 was implicated in exacerbated COVID-19-associated kidney injury56. Elution of CD99 peptides in the urine separated groups of patients with mild versus severe kidney pathology; in addition, CD99+ lymphocytes were found in significantly lower percentages in patients with severe outcomes. The authors speculated that aberrant autoimmune responses directed against CD99 may be promoting the exacerbation of kidney injury, and that this reduction of CD99 overall could indicate a loss of endothelial integrity56. Recently, Domizio and colleagues found that acute respiratory injury following SARS-CoV-2 infection is in part due to lung endothelial damage, which they speculated translated to other organ systems as well57. Neuropathogenesis following SARS-CoV-2 infection has been noted for distinct pathophysiological patterns, including loss of blood–brain barrier (BBB) integrity58, which is structurally maintained largely through endothelial cells59. Integral to these observations is the finding that Keratin Type II Cytoskeleton 6A (a protein recovered in our original PEPMatch analysis, Fig. 1G) was also found to be dysregulated in patients with severe kidney injury56. This keratin protein has been associated with wound healing, in which loss of this protein led to profound inabilities of mice to undergo normal wound healing processes60. The peptides identified from PEPMatch (Fig. 1G), and more specifically those predicted to be bound and presented on MHC (Fig. 3C) warrant further experimental investigation, as they collectively suggest a mechanism by which molecular mimicry initiated by SARS-CoV-2 infection could lead to the inappropriate targeting of proteins involved in a range of biological processes necessary for a multitude of organ systems, culminating in severe neurological and other pathological outcomes.
Molecular mimicry has been explored as a mechanism for triggering MS for decades, and several viral and bacterial pathogens have been associated with MS development61. The most strongly linked etiological agent of MS is Epstein-Barr virus (EBV), in which multiple recent studies have strongly implicated the development of MS with EBV infection62,63. In our own hands using PEPMatch, we were able to demonstrate that a larger proportion of EBV proteins share similarity with MS-associated proteins than its virologic cousin, cytomegalovirus (CMV), aligning with current views on MS etiology and substantiating the practicality and utility of PEPMatch as a new resource (Supplemental Fig. 1). Seasonal coronaviruses have also been implicated in the pathogenesis of MS using a range of bioinformatic and clinical approaches27,28,29. Primary T cell clones isolated from MS patients activated with HCoV-229E and HCoV-OC43 proteins cross-reacted with myelin basic protein (MBP) and PLP, highlighting the propensity for viral molecular mimicry involving seasonal coronaviruses29. In our study, we found that nucleocapsid protein from 3 out of the 4 major seasonal coronaviruses showed significant sequence overlap with MS-associated proteins (Fig. 4A); however, this effect was only found in the 15mer group, whose threshold for peptide sequence overlap is around 50%17; this indicates a greater percentage of exact sequence matching and overall homology of SARS-CoV-2 nucleocapsid to MS proteins. In addition, we found that no myelin proteins shared homology with any coronaviruses except for PLP and SARS-CoV-2. Discussion has arisen querying whether the SARS-CoV-2 pandemic will herald an increase in MS incidence64. Our results provide a computational basis for this hypothesis, which should be further investigated using epidemiological approaches.
Here, we utilized a new homology-based package called PEPMatch to determine the sequence overlap between immunodominant proteins from SARS-CoV-2 and proteins associated with MS. We found that nucleocapsid significantly overlapped with MS-associated proteins, including PLP. Our work suggests that a variety of proteins may be involved in triggering autoimmunity associated with MS pathogenesis in certain individuals. We chose to focus our analysis on understanding T-cell-driven molecular mimicry, though the creation and maintenance of autoantibodies has been strongly implicated in both MS and COVID-19 severity38,65. Recent reports have shown that nucleocapsid is critical in driving humoral immunity in both SARS-CoV66 and SARS-CoV-267. Future integrated experimental and computational efforts should focus on understanding the full breadth of autoimmunity following SARS-CoV-2 infection, including the involvement of other organ systems and both adaptive immune arms, for a more comprehensive understanding of pathological sequelae of SARS-CoV-2.
MS-associated antigens were compiled using the Immune Epitope Database and Analysis Resource (http://www.iedb.org/). The search included the following parameters: “Organism: Homo Sapiens”, “Include Positive Assays”, “No B Cell Assays”, “Disease Data: Multiple Sclerosis (DOID:2377)”, and “MHC Restriction Type: Class I” (class I restriction was added to ensure that many proteins associated with both class I and class II were included in the analysis, as the vast majority of the 1200 + proteins discovered without filtering were associated only with class II). Finally, proteins were added which have been associated strongly with MS in the literature that did not originally appear in the IEDB filtering68. This list was trimmed down to proteins which had updated UniProt IDs, leading to the list of 108 MS-associated antigens used in this analysis. This list, with UniProt IDs, can be found in Table 1. Complete list of query proteins in this analysis, including proteins from SARS-CoV-2 and seasonal coronaviruses, as well as EBV and CMV proteins, can also be found in Table 1.
Homology between SARS-CoV-2 immunodominant proteins and the list of MS-associated proteins was conducted primarily using PEPMatch and BLASTp. All code utilized in this analysis can be found on GitHub using the following link: https://github.com/mad-scientist-in-training/PEPMatch_SARS-CoV-2_MS.
PEPMatch is a homology-based algorithm developed by Daniel Marrama17 and is freely available to use on GitHub: https://github.com/IEDB/PEPMatch. PEPMatch was utilized to preprocess the list of MS-associated proteins and query proteins (found in Table 1). Custom python scripts were created to utilize PEPMatch and perform all other processing necessary to run the package (see Homology Assessment for link to GitHub page). Parameters were set to preprocess all data sets separately into 9mer peptides and 15mer peptides, with 2 and 7 mismatches respectively. PEPMatch output for all significant tests is available in Supplemental Table 1.
To determine homology between PEPMatch-predicted peptides overlapping with nucleocapsid and experimentally validated epitopes (Fig. 2A), a list of epitopes for each protein was compiled using the IEDB. The search parameters included “Antigen: Protein_of_interest (Homo sapiens (human))”, “Include Positive Assays”, and “Host: Homo sapiens (human)”. Standard Protein BLAST (BLASTp) was used to determine the homology between all PEPMatch-predicted epitopes and experimentally validated peptides for each protein. To normalize, the total number of homology “hits” returned from BLASTp was divided by the number of peptides predicted from PEPMatch for each protein.
Example BLASTp analysis: PLP.
Peptides returned from PEPMatch (overlapping with nucleocapsid):
Epitopes returned from IEDB query:
Number of Homology “hits” from BLASTp analysis
Normalized total hits
20/1 = 20
BLASTp was also used to determine the percent identity between nucleocapsid from SARS-CoV-2 and seasonal coronaviruses using the standard, recommended parameters.
For statistical comparisons, each query protein (spike, nucleocapsid, and membrane, NS7a, replicase polyprotein1ab, and envelope) was separately processed to provide “background” number of hits against MS-associated proteins. Specifically, custom python scripts (found on the GitHub page) were created to shuffle the amino acid sequence of each query protein, which were run to determine the number of matches with MS-associated proteins as background matching signal. Duplicate matches (for example, if identical peptides from 2 separate MS-associated proteins matched a SARS-CoV-2-derived peptide) were removed prior to statistical testing. For each query protein tested, 30 iterations of unique shuffled comparisons were run, which were then averaged and used in a Fisher’s exact or Chi-square test for statistical comparison. All analyses were run conservatively with two-tailed parameters; however, if the number of random matches exceeded the number of matches of the intact peptide, the p value was assumed to be 1. The following is an example of the statistics utilized for each protein in this analysis:
Match in MS proteins
No match in MS proteins
Shuffle Peptides (avg)
Match in MS Proteins
No Match in MS Proteins
Shuffle Peptides (avg)
Statistical analyses (as above) for all comparisons in this manuscript can be found in Supplemental Table 2.
3D structure of PLP
Structural visualization of myelin proteolipid protein (PLP) was conducted using AlphaFold69 and ChimeraX70,71. Specifically, AlphaFold-simulated structure of PLP (ID: P60201) was loaded into ChimeraX for manipulation and visualization. Protein regions of PLP identified to be immunodominant, specifically regions 40–60, 95–117, 117–150, and 185–20620, were highlighted and colored for accentuation. The sequence of PLP used throughout the analysis can be found on UniProt (https://www.uniprot.org/).
The MHC binding prediction machine learning algorithm from the IEDB was used to determine whether MS-associated alleles were predicted to preferentially bind and present nucleocapsid peptides in comparison to a reference set of alleles. MS-associated alleles were curated from the literature22,23,24 and used in comparison to an allele set from the IEDB that covers 99% of the population25. Nucleocapsid peptide “hits” from PEPMatch were used in the query against the total set of alleles (MS and reference) using the IEDB recommended 2.22 standard parameter. As most binding predictions were skewed heavily towards high percentile ranks, the top 50% percentile of all matching predictions were focused on to capture information for all alleles input while also providing physiologically relevant binding information. In Fig. 3C, the nucleocapsid peptide-MHC binding predictions of percentile rank 10 or less26 were cross-referenced with the original PEPMatch output to determine the homologous MS-associated proteins, and the frequency of peptide matches were tabulated and graphed.
Graphics in this article were created using Biorender (https://biorender.com/).
The authors declare that all data in support of the main findings of this study are available within the paper and its supplementary information files. All other data (including raw data generated in the supplemental findings) are available upon reasonable request to the corresponding author.
All code generated for this project is available on GitHub at the following repository: https://github.com/mad-scientist-in-training/PEPMatch_SARS-CoV-2_MS.
Coronavirus disease (COVID-19)—World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
Aghagoli, G. et al. Neurological involvement in COVID-19 and potential mechanisms: A review. Neurocrit. Care 34, 1062–1071 (2021).
Nasserie, T., Hittle, M. & Goodman, S. N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: A Systematic review. JAMA Netw. Open 4, e2111417 (2021).
Ismail, I. I. & Salama, S. Association of CNS demyelination and COVID-19 infection: an updated systematic review. J. Neurol. https://doi.org/10.1007/s00415-021-10752-x (2021).
Number of people with MS | Atlas of MS. https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms.
Liblau, R. & Gautam, A. M. HLA, molecular mimicry and multiple sclerosis. Rev. Immunogenet. 2, 95–104 (2000).
Wekerle, H. & Hohlfeld, R. Molecular mimicry in multiple sclerosis. N. Engl. J. Med. 349, 185–186 (2003).
Chastain, E. M. L. & Miller, S. D. Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease. Immunol. Rev. 245, 227–238 (2012).
Dykema, A. G. et al. Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. J. Clin. Investig. 131, (2021).
Toscano, G. et al. Guillain–Barré syndrome associated with SARS-CoV-2. N. Engl. J. Med. 382, 2574–2576 (2020).
Olson, J. K., Eagar, T. N. & Miller, S. D. Functional activation of myelin-specific T cells by virus-induced molecular mimicry. J. Immunol. 169, 2719–2726 (2002).
Krishnamoorthy, G. & Wekerle, H. EAE: An immunologist’s magic eye. Eur. J. Immunol. 39, 2031–2035 (2009).
Joshi, S. K., Suresh, P. R. & Chauhan, V. S. Flexibility in MHC and TCR recognition: Degenerate specificity at the T cell level in the recognition of promiscuous th epitopes exhibiting no primary sequence homology. J. Immunol. 166, 6693–6703 (2001).
Lang, H. L. E. et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3, 940–943 (2002).
Fujinami, R. S., Oldstone, M. B., Wroblewska, Z., Frankel, M. E. & Koprowski, H. Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. PNAS 80, 2346–2350 (1983).
Nath, A. & Wolinsky, J. S. Antibody response to rubella virus structural proteins in multiple sclerosis. Ann. Neurol. 27, 533–536 (1990).
Marrama, D., Mahita, J., Sette, A. & Peters, B. Lack of evidence of significant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens. eBioMedicine 75, (2022).
Markovic-Plese, S. et al. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J. Immunol. 155, 982–992 (1995).
Pelfrey, C., Tranquill, L., Vogt, A. & McFarland, H. T cell response to two immunodominant proteolipid protein (PLP) peptides in multiple sclerosis patients and healthy controls. Mult. Scler. 1, 270–278 (1996).
Trotter, J. L. et al. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J. Neuroimmunol. 84, 172–178 (1998).
Macdonald, W. A. et al. T cell allorecognition via molecular mimicry. Immunity 31, 897–908 (2009).
Weinshenker, B. G. et al. Major histocompatibility complex class II alleles and the course and outcome of MS: A population-based study. Neurology 51, 742–747 (1998).
Zivadinov, R. et al. HLA‐DRB1*1501, ‐DQB1*0301, ‐DQB1*0302, ‐DQB1*0602, and ‐DQB1*0603 Alleles are Associated With More Severe Disease Outcome on Mri in Patients With Multiple Sclerosis. in International Review of Neurobiology vol. 79 521–535 (Academic Press, 2007).
Patsopoulos, N. A. et al. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet 9, e1003926 (2013).
Greenbaum, J. et al. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics 63, 325–335 (2011).
Selecting thresholds (cut-offs) for MHC class I and II binding predictions. IEDB Solutions Center https://help.iedb.org/hc/en-us/articles/114094151811-Selecting-thresholds-cut-offs-for-MHC-class-I-and-II-binding-predictions.
Jouvenne, P., Mounir, S., Stewart, J. N., Richardson, C. D. & Talbot, P. J. Sequence analysis of human coronavirus 229E mRNAs 4 and 5: Evidence for polymorphism and homology with myelin basic protein. Virus Res 22, 125–141 (1992).
Murray, R. S., Brown, B., Brain, D. & Cabirac, G. F. Detection of coronavirus RNA and antigen in multiple sclerosis brain. Ann. Neurol. 31, 525–533 (1992).
Talbot, P. J., Boucher, A., Duquette, P. & Gruslin, E. Coronaviruses and Neuroantigens: myelin proteins, myelin genes. Exp. Models Mult. Scler. https://doi.org/10.1007/0-387-25518-4_43 (2005).
Ellul, M. A. et al. Neurological associations of COVID-19. Lancet Neurol. 19, 767–783 (2020).
Wu, Y. et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav. Immun. 87, 18–22 (2020).
Thieme, C. et al. The SARS-COV-2 T-Cell Immunity is Directed Against the Spike, Membrane, and Nucleocapsid Protein and Associated with COVID 19 Severity. https://papers.ssrn.com/abstract=3606763 (2020). https://doi.org/10.2139/ssrn.3606763.
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489-1501.e15 (2020).
Tarke, A. et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep. Med. 2, 100204 (2021).
Jordan, S. C. et al. T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. Cell Mol. Immunol. 18, 2554–2556 (2021).
Gangaev, A. et al. Profound CD8 T cell responses towards the SARS-CoV-2 ORF1ab in COVID-19 patients. https://www.researchsquare.com/article/rs-33197/v1 (2020). https://doi.org/10.21203/rs.3.rs-33197/v1.
Tilocca, B. et al. Immunoinformatic analysis of the SARS-CoV-2 envelope protein as a strategy to assess cross-protection against COVID-19. Microbes Infect. 22, 182–187 (2020).
Shaw, S. Y., Laursen, R. A. & Lees, M. B. Analogous amino acid sequences in myelin proteolipid and viral proteins. FEBS Lett. 207, 266–270 (1986).
Amor, S., Baker, D., Groome, N. & Turk, J. L. Identification of a major encephalitogenic epitope of proteolipid protein (residues 56–70) for the induction of experimental allergic encephalomyelitis in Biozzi AB/H and nonobese diabetic mice. J. Immunol. 150, 5666–5672 (1993).
Greer, J. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 120, 1447–1460 (1997).
Dayhoff, M. O., Barker, W. C. & Hunt, L. T.  Establishing homologies in protein sequences. in Methods in Enzymology vol. 91 524–545 (Academic Press, 1983).
França, L. C. et al. Molecular Mimicry between Zika virus and central nervous system inflammatory demyelinating disorders: the role of NS5 Zika virus epitope and PLP autoantigens. at https://doi.org/10.21203/rs.2.22564/v1 (2022).
He, X. et al. Structural snapshot of aberrant antigen presentation linked to autoimmunity: The immunodominant epitope of MBP complexed with I-Au. Immunity 17, 83–94 (2002).
IPD-IMGT/HLA Database. https://www.ebi.ac.uk/ipd/imgt/hla/alleles/.
van Gerven, N. M. F. et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun 16, 247–252 (2015).
Hu, F. et al. Novel findings of HLA association with anti-LGI1 encephalitis: HLA-DRB1*03:01 and HLA-DQB1*02:01. J. Neuroimmunol. 344, 577243 (2020).
Alvarenga, M. P. et al. The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro. J. Neuroimmunol. 310, 1–7 (2017).
Skinningsrud, B. et al. Multiple loci in the HLA complex are associated with Addison’s disease. J. Clin. Endocrinol. Metab. 96, E1703–E1708 (2011).
Bhattarai, P., Allen, H., Aggarwal, A., Madden, D. & Dalton, K. Unmasking of Addison’s disease in COVID-19. SAGE Open Med. Case Rep. 9, 2050313X211027758 (2021).
Oğuz, S. H. & Gürlek, A. Emergence of Autoimmune Type 1 Diabetes and Acute Adrenal Crisis Following COVID-19. https://www.researchsquare.com/article/rs-1015570/v1 (2021). https://doi.org/10.21203/rs.3.rs-1015570/v1.
Sánchez, J., Cohen, M., Zapater, J. L. & Eisenberg, Y. Primary adrenal insufficiency after COVID-19 infection. AACE Clin. Case Rep. https://doi.org/10.1016/j.aace.2021.11.001 (2021).
Langton, D. J. et al. The influence of HLA genotype on the severity of COVID-19 infection. HLA 98, 14–22 (2021).
Migliorini, F. et al. Association between HLA genotypes and COVID-19 susceptibility, severity and progression: a comprehensive review of the literature. Eur. J. Med. Res. 26, 84 (2021).
Tavasolian, F. et al. HLA, Immune response, and susceptibility to COVID-19. Front. Immunol. 11, (2021).
Pasello, M., Manara, M. C. & Scotlandi, K. CD99 at the crossroads of physiology and pathology. J. Cell Commun. Signal 12, 55–68 (2018).
Siwy, J. et al. CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID-19: A potential link to molecular pathophysiology?. Proteomics 21, 2100133 (2021).
Di Domizio, J. et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature https://doi.org/10.1038/s41586-022-04421-w (2022).
Schwabenland, M. et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity 54, 1594-1610.e11 (2021).
Engelhardt, B. Development of the blood-brain barrier. Cell Tissue Res. 314, 119–129 (2003).
Wong, P. & Coulombe, P. A. Loss of keratin 6 (K6) proteins reveals a function for intermediate filaments during wound repair. J. Cell Biol. 163, 327–337 (2003).
Libbey, J. E., McCoy, L. L. & Fujinami, R. S. Molecular Mimicry in Multiple Sclerosis. in International Review of Neurobiology vol. 79 127–147 (Academic Press, 2007).
Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science https://doi.org/10.1126/science.abj8222 (2022).
Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature https://doi.org/10.1038/s41586-022-04432-7 (2022).
Shalaby, N. M. & Shehata, H. S. Could SARS-CoV-2 herald a surge of multiple sclerosis?. Egypt J. Neurol. Psychiatry Neurosurg. 57, 22 (2021).
Song, E. et al. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep. Med. 2, 100288 (2021).
Liang, Y. et al. Comprehensive antibody epitope mapping of the nucleocapsid protein of severe acute respiratory syndrome (SARS) coronavirus: Insight into the humoral immunity of SARS. Clin. Chem. 51, 1382–1396 (2005).
Smits, V. A. J. et al. The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients. Biochem. Biophys. Res. Commun. 543, 45–49 (2021).
Sun, J. et al. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J. Immunol. 146, 1490–1495 (1991).
AlphaFold Protein Structure Database. https://alphafold.ebi.ac.uk/.
Goddard, T. D. et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).
Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
Rickinson, A. B. & Moss, D. J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15, 405–431 (1997).
Moss, P. & Khan, N. CD8+ T-cell immunity to cytomegalovirus. Hum. Immunol. 65, 456–464 (2004).
We thank Avindra Nath, Thomas Esch, Daniel Rotrosen, Charles Hackett, Alison Deckhut-Augustine, and members of the Division of Allergy, Immunology, and Transplantation (DAIT) at the National Institute of Allergy and Infectious Diseases (NIAID) for discussions about this project. In addition, we acknowledge Daniel Marrama, Bjoern Peters, Alessandro Sette, and those at the La Jolla Institute for Immunology for creating PEPMatch and providing expert advice and support during project development. This research was supported in part by an appointment to the National Institute of Allergy and Infectious Diseases (NIAID) Emerging Leaders in Data Science Research Participation Program. This program is administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the National Institutes of Health.
Open Access funding provided by the National Institutes of Health (NIH).
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lake, C.M., Breen, J.J. Sequence similarity between SARS-CoV-2 nucleocapsid and multiple sclerosis-associated proteins provides insight into viral neuropathogenesis following infection. Sci Rep 13, 389 (2023). https://doi.org/10.1038/s41598-022-27348-8
This article is cited by
BMC Microbiology (2023)